COSENTYX (secukinumab) Patient Assistance Program
Don’t let the high cost of brand specialty IL-17A biologic therapy disrupt your treatment. We help eligible patients access Cosentyx (secukinumab) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Cosentyx (secukinumab) is FDA-approved for moderate-to-severe plaque psoriasis (adults and pediatric ≥6 years), psoriatic arthritis (adults and pediatric ≥2 years), ankylosing spondylitis (adults), non-radiographic axial spondyloarthritis (adults), enthesitis-related arthritis (pediatric ≥4 years), and hidradenitis suppurativa (adults). It is an IL-17A inhibitor given as a subcutaneous injection.
- Without assistance, Cosentyx costs commonly run approximately $6,500–$7,500 per monthly maintenance dose, with annual costs commonly $80,000–$95,000+.
- Through AffordMyPrescriptions, qualifying patients can access Cosentyx for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no biosimilar of Cosentyx in the U.S. as of 2026. Other IL-17 inhibitors include ixekizumab (Taltz), brodalumab (Siliq, IL-17 receptor), and bimekizumab (Bimzelx, dual IL-17A/IL-17F). TNF biosimilars (for Humira/adalimumab and Remicade/infliximab) and IL-23 inhibitors (Tremfya, Skyrizi, Ilumya) are also alternatives in many of the same indications.
What Is Cosentyx Prescription Assistance Program?
The Cosentyx Prescription Assistance Program is a manufacturer-sponsored initiative that provides Cosentyx at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for psoriasis, psoriatic arthritis, axial spondyloarthritis, and other approved indications in patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, dermatology/rheumatology coordination, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification.
Pharmacy Price Comparison
- Without assistance, Cosentyx costs roughly $6,500–$7,500 per monthly maintenance dose. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$7,300/dose | Save ~$7,230/dose |
| CVS Pharmacy | ~$7,500/dose | Save ~$7,430/dose |
| Walmart | ~$6,700/dose | Save ~$6,630/dose |
| Costco | ~$6,600/dose | Save ~$6,530/dose |
Specialty Pharmacy | ~$6,900/dose | Save ~$6,830/dose |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Cosentyx Prescription Program?
The Patient Assistance Program is free to apply for and provides Cosentyx at no medication cost if approved. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Cosentyx:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $6,500–$7,500 per dose per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Cosentyx assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Cosentyx Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Cosentyx:
Cosentyx (secukinumab) is a fully human IgG1κ monoclonal antibody that selectively binds and neutralizes interleukin-17A (IL-17A) — a key cytokine driving inflammation in psoriasis, psoriatic arthritis, axial spondyloarthritis, and several other immune-mediated conditions. It is given as a subcutaneous injection.
How Cosentyx Works:
Many chronic inflammatory diseases (psoriasis, psoriatic arthritis, ankylosing spondylitis) are driven by the IL-23/Th17 axis. Th17 cells produce IL-17A, which acts on keratinocytes (in skin) and other tissues to drive inflammation, immune-cell recruitment, and tissue remodeling. Blocking IL-17A interrupts this inflammatory cascade.
Secukinumab is a monoclonal antibody that binds IL-17A and prevents it from activating its receptor on target cells. The result is rapid reduction of skin inflammation in psoriasis (often dramatic clearing within weeks), reduced joint inflammation in psoriatic arthritis and axial spondyloarthritis, and clinical benefit in other IL-17-driven conditions. IL-17 inhibitors are typically very effective for skin clearance in psoriasis but may be less effective than IL-23 inhibitors for some patients; rheumatology indications also vary.
Form and use:
Cosentyx is given as a subcutaneous injection. Standard adult psoriasis dosing: 300 mg at weeks 0, 1, 2, 3, and 4 (loading), then 300 mg every 4 weeks. For psoriatic arthritis and axial spondyloarthritis, dosing varies (150 mg or 300 mg every 4 weeks). Self-injected at home using a Sensoready pen, prefilled syringe, or UnoReady pen. TB screening required before starting.
Generic availability:
There is no biosimilar of Cosentyx in the U.S. as of 2026. Other IL-17 pathway inhibitors include ixekizumab (Taltz, IL-17A), brodalumab (Siliq, IL-17 receptor), and bimekizumab (Bimzelx, dual IL-17A/IL-17F). For the same indications, IL-23 inhibitors include Tremfya (guselkumab), Skyrizi (risankizumab), and Ilumya (tildrakizumab). TNF biosimilars (adalimumab biosimilars for Humira, infliximab biosimilars for Remicade) are widely available at lower cost than brand TNF blockers.
Warnings:
Cosentyx carries warnings for serious infections (including TB reactivation — screening required before starting), inflammatory bowel disease (new onset or worsening of Crohn’s disease or ulcerative colitis — Cosentyx is generally avoided in patients with active IBD), hypersensitivity reactions, and avoidance of live vaccines. Latex allergy: the cap of certain prefilled syringes contains latex.
FAQ (Frequently Asked Questions)
How Much Does Cosentyx Cost Without Insurance?
Cosentyx costs approximately $6,500–$7,500 per monthly maintenance dose. Annual costs commonly $80,000–$95,000+. Through AffordMyPrescriptions, qualifying patients receive Cosentyx at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
How Quickly Will Cosentyx Work?
For plaque psoriasis, many patients see significant skin improvement within 2–4 weeks of starting, with peak response typically at 12–16 weeks. For psoriatic arthritis and axial spondyloarthritis, joint symptoms often improve within 4–8 weeks. Cosentyx is one of the faster-acting biologics for skin clearance in psoriasis.Cortifoam: hydrocortisone (moderate potency, more systemic absorption). Uceris foam: budesonide (higher first-pass metabolism — less systemic exposure; preferred for longer-term use; brand only). Generic hydrocortisone foam much cheaper but more systemic exposure with long-term use.
How Is Cosentyx Different From Taltz Or Skyrizi?
Cosentyx (secukinumab) and Taltz (ixekizumab) both block IL-17A directly. Bimzelx (bimekizumab) blocks both IL-17A and IL-17F (potentially greater skin efficacy). Siliq (brodalumab) blocks the IL-17 receptor (and carries a boxed warning for suicidal ideation, with REMS). Skyrizi, Tremfya, and Ilumya are IL-23 inhibitors — also very effective for psoriasis but with different dosing intervals (Skyrizi every 12 weeks after loading). Choice depends on indication, dosing preferences, comorbidities (especially IBD — IL-23 inhibitors are preferred over IL-17 inhibitors if IBD coexists), and tolerability.
Why Do I Need TB Testing Before Cosentyx?
Biologics that affect the immune system can reactivate latent tuberculosis. TB screening (PPD or QuantiFERON-Gold) is required before starting. Patients with positive screening typically need TB prophylaxis (isoniazid or rifapentine-isoniazid) before or alongside Cosentyx.
Can I Get Cosentyx If I Have Inflammatory Bowel Disease?
Generally no. IL-17 inhibitors (Cosentyx, Taltz, Siliq, Bimzelx) can trigger or worsen IBD. Patients with active or recent IBD typically receive IL-23 inhibitors (Tremfya, Skyrizi) or TNF inhibitors instead, which can simultaneously treat both psoriasis/PsA and IBD.Avoid prolonged use due to systemic steroid effects with long-term hydrocortisone. Budesonide foam (Uceris) preferred for longer courses. For chronic maintenance, mesalamine products preferred.
Can I Get Cosentyx Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
What If My Application Is Denied?
If denied, we explore alternatives — switching to a different biologic with its own PAP (Taltz, Skyrizi, Tremfya, or a TNF biosimilar at much lower cost), the manufacturer’s copay program for commercially insured patients, or independent foundations such as the National Psoriasis Foundation, Spondylitis Association of America, Arthritis Foundation, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee
Take Control of Your Medication Costs
If you are struggling with the high cost of Cosentyx, our team may be able to help you access assistance programs designed to make brand specialty IL-17A biologic therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.